Developing vaccines based on viral-like particles (VLPs) can be beneficial. VLPs represent viral antigens that resemble viruses in nature. Unlike viruses that can replicate inside their host causing infection, VLPs have no capability to replicate and cause infection due to the lack of a viral genome. These properties make VLPs a preferable vaccine rather than inactivated viruses. In this research, VLPs were produced using a baculovirus infection system. Upon infection in SF9 insect cells, recombinant baculovirus produces new baculovirus proteins as well as the influenza proteins hemagglutinin (HA), neuraminidase (NA), and matrix (M1) protein, which can auto assemble into VLPs. VLPs can be separated from baculovirus using an ultracentrifuge. The first step of VLP production is selection of the baculovirus with recombinant genes encoding influenza proteins. The obstacle in selecting recombinant baculovirus is that infected SF9 cells do not produce specific cytopathogenic effects. To assist in the observation of baculovirus production in SF9 cells, we developed a protein reporter system for recombinant baculovirus production. Enhanced green fluorescent protein (eGFP) was used as a reporter protein. The gene encoding eGFP was cloned into the same transient plasmid that also encodes HA, NA, and matrix protein M1. Those proteins were expressed under four different open reading frames. This plasmid was co-transfected with a linearized baculovirus genome. Structural proteins of baculovirus and VLP forming recombinant proteins as well as the reporter protein were produced. Structural proteins of the baculovirus together with the genome of the baculoviruscontaining recombinant genes would co-assemble, producing recombinant baculovirus. The recombinant proteins then assembled, producing VLPs, and expression of the reporter protein eGFP would be visible in the cytoplasm by fluorescence microscopy. Using a TALI cytometer, the percentage of cells that produced GFP was determined to be 3% of the total population, indicating that eGFP can be used to observe the production of recombinant baculovirus in SF9 cells. The infectivity of baculovirus
Introduction
Although poultry is an H5N1 influenza virus host, this virus can also infect humans with serious manifestation. Human can be infected by H5N1 by contact with poultry or their products. Evidence of human-to-human infection does not exist except in 'family cluster' cases. The presence of H5N1 infection in poultry and various animals needs to be watched out. This is based on the ability of the H5N1 virus genome to recombine and undergo spontaneous mutation, which can alter the virus profile, allowing it to adapt to horizontal infection [1] .
As the chances of human-to-human infection of new strains of H5N1 have increased, vaccine development is ongoing. One of the H5N1 vaccines developed is a viral-like particle (VLP). VLPs have a virus-like structure without the viral genome. This influenza VLP consists of virus surface glycoprotein, hemagglutinin (HA), neuraminidase (NA), and matrix protein M1. As a multiprotein vaccine, VLPs have advantages compared to subunit or inactivated vaccines. VLPs has a virus-like immunogenicity because the antigens carried have the same antigenic structure as viruses. It is also considered safer because it does not contain genetic material. The influenza virus has the ability to recombine genomes with other influenza virus subtypes. This recombination will produce new viruses with new characteristics [2] . Based on this theory, VLPs can be helpful in preventing recombinant viruses with a new genome.
VLPs are made by cloning VLP genes into a transient plasmid. The protein-coding genes were cloned into one plasmid type in which each protein is expressed under p10 promoter and terminator. Following this, the transient plasmid is co-transfected into SF9 insect cells along with the linearized baculovirus genome. In SF9 cells, the transient plasmid and linearized baculovirus genome recombine to produce a full baculovirus genome that produces recombinant baculovirus that contains recombinant protein-producing genes [3] .
There are some issues with the VLP-based vaccine production technique, such as the observation of baculovirus-infected cells because damaged cells are not evident. 
Material and Method

pBAcH5N1MeGFP plasmid pBAcH5N1MeGFP plasmid
The transient plasmid consisted of VLP-protein coding genes, including HA, NA, M1, and eGFP. Each plasmid was expressed under a p10 promoter. 
Baculogold and recombinant transient vector coinfection
Baculogold 
Recombinant baculovirus infection in SF9 cells
Tali image-based cytometer
Cells were diluted with PBS to a concentration of 5x10 5 cells/mL and the number of fluorescent cells was counted. Then, 25 μL of diluted cells were placed on a Tali slide (Invitrogen), which was inserted into Tali image-based cytometer (Invitrogen).
Result and Discussion
Naturally, baculovirus is a virus that attacks Autographa california (Ac), an alfalfa looper. The morphological changes of SF9 cells indicated that the recombinant baculovirus affected these cells. Baculovirus-infected cells will undergo fusion [6] . Fusion of infected cells results in multinucleated and clumping cells. Baculovirus infection will also induce cells to enter a resting G2/M phase, resulting in cell death [7] . In general, the disruption of cell cycle will result in apoptosis, which is evident morphologically by cell swelling.
Following this, protrusions are formed on the cell membrane. After swelling to a certain volume, cells are fragmented into smaller sizes [8] . This apoptotic phenomenon was also observed in recombinant baculovirus infected-cells (Figure 2 ).
The addition of the marker protein eGFP allowed for the differentiation of infected recombinant baculovirus cells that produce recombinant proteins carried by the baculovirus. Some studies have investigated the use of eGFP as a baculovirus marker [9] .
In one study, eGFP was expressed as a baculovirus structural protein. The addition of eGFP has been shown to help in the plaque selection process, which was performed using UV light at 365 nm. In this research, eGFP was expressed separately, not as part of the baculovirus structural or VLP proteins. On the third viral passage, approximately 3% of cells were eGFP-positive (Figure 3 ). Based on fluorescence microscopy, eGFP fluorescence was not high in intensity ( Figure 4) ; the intensity was correlated with the molecular amount in cells.
On the fourth passage, an increased number of fluorescent cells were observed (Figure 5 ), indicating that more eGFP was expressed. This is hypothesized to be caused by the recombinant baculovirus, which can produce the recombinant protein, eGFP, with high intensity.
Thus, recombinant baculovirus was produced, but the capacity to infect was still low, To obtain infectious baculovirus, the plaque test must be performed to screen recombinant baculovirus, which has a high infectious ability. used to analyze recombinant proteins, and PCR can be performed to determine if the recombinant baculovirus is present.
